Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
- Oct 26, 2021
Completion of Enrollment in 1st US Clinical Trial & Achievement of 1st Primary Objective
JERUSALEM, Oct. 25, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its US pilot trial for skin cancer has completed enrollment as planned. This announcement comes less than four months after the first patient was recruited into the trial in July 2021. Alpha DaRT sources were successfully implanted into all patients and then removed two to three weeks later as scheduled, and no seri
- Oct 12, 2021
Meet Alpha Tau at ASTRO Chicago 2021
We are thrilled to announce that the Alpha Tau team will be attending (IN PERSON this year - Finally ! ) the ASTRO conference in Chicago. We won't miss this great opportunity to meet and discuss with the radiation oncology society our upcoming US multicenter pivotal skin trial and the use of Alpha DaRT technology for new indications such as prostate, GBM, lung and more. We will be delighted to meet you at our booth #1706 and have an applicator demonstration. (View floor plan
- Oct 12, 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
JERUSALEM, Oct. 8, 2021 -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to announce that it has received Breakthrough Device Designation for Alpha DaRT from the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent glioblastoma multiforme (GBM). This is the second Breakthrough Device Designation that Alpha Tau has received from the FDA, following its announcement on June 8, 2021 of the